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Abstract
Background: The causes of chronic low back pain (CLBP) remain obscure and effective treatment
of symptoms remains elusive. A mechanism of relieving chronic pain based on the consequences of
conflicting unpleasant sensory inputs to the central nervous system has been hypothesised. As a
result a device was generated to deliver sensory discrimination training (FairMed), and this
randomised controlled trial compared therapeutic effects with a comparable treatment modality,
TENS.
Methods: 60 patients with CLBP were recruited from physiotherapy referrals to a single-blinded,
randomised controlled, non-inferiority trial. They were randomised to receive either FairMed or
TENS and asked to use the allocated device for 30 minutes, twice a day, for 3 weeks. The primary
outcome variable measured at 0 and 3 weeks was pain intensity measured using a visual analogue
scale averaged over 7 days. Secondary outcome measures were Oswestry Disability Index, 3 timed
physical tests, 4 questionnaires assessing different aspects of emotional coping and a global measure
of patient rating of change. Data were analysed for the difference in change of scores between
groups using one-way ANOVA.
Results: Baseline characteristics of the two groups were comparable. The primary outcome,
change in pain intensity (VAS) at 3 weeks showed a mean difference between groups of -0.1, (non
significant p = 0.82). The mean difference in change in ODI scores was 0.4; (non significant p = 0.85).
Differences in change of physical functioning showed that no significant difference in change of
scores for any of these test (p = 0.58 – 0.90). Changes in scores of aspects of emotional coping also
demonstrated no significant difference in change scores between the groups (p = 0.14 – 0.94).
Conclusion: FairMed was not inferior to TENS treatment.
The findings have implications for further research on current chronic pain theories and
treatments. Further work to explore these mechanisms is important to expand our understanding
of chronic pain and the role of neuro-modulation.
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Chronic low back pain (CLBP) is a very common symp-
tom, and a major source of distress. The causes of back
pain remain obscure and effective treatment of symptoms
remains elusive. Most treatments are empirical, and few
have withstood close scrutiny for effectiveness [1].
One approach is to understand the underlying causes, so
that we can develop rational treatments. Current hypoth-
eses of the basis of back pain can be broadly viewed as:
1. Biomedical or "Cartesian" models, where a pain
sources or sources stimulate a pain pathway to the brain.
2. A bio psychosocial model.
This study arose because the senior investigator (JF) has
become increasingly dissatisfied with Cartesian explana-
tions for back pain, particularly following the MRC Spine
Stabilisation Trial [2] where similar results were obtained
in a Cartesian model (spinal fusion) and a non-cartesian
model (intensive rehabilitation). In this light, the Harris
hypothesis of conflicting sensory input is attractive [3],
and lead to the development of a novel device to try to
reduce this conflict.
Harris [3] proposed a hypothesis for a mechanism of
chronic pain based on the consequences of conflicting
sensory input to the central nervous system generating
unpleasant sensations. He called this cortical pain. Flor et
al [4] used a cortical pain model in a study that showed
improving sensory discrimination for patients with intrac-
table phantom limb pain led to cortical reorganisation
and significant reductions in their pain.
Device treatment for pain has some obvious advantages
over pharmaceutical treatments, particularly that nothing
has to be ingested and the side effect profile is likely to be
much less. It is also likely to be cheaper than pharmaceu-
tical management and can be used in conjunction with
those rehabilitation treatments for which there is evidence
of efficacy. Device treatment is likely to have a potent pla-
cebo effect. There are many devices that purport to treat
back pain. The current "market leader" is transcutaneous
electrical nerve stimulation (TENS), estimated to be 1% of
the analgesic market for back pain The treatment effect of
TENS is attributed to influencing the "gate" proposed by
Melzack and Wall in their Gate Control Theory of Pain
[5]. TENS has been commercially successful. However, the
clinical benefits of TENS remain controversial and there is
lack of consensus regarding its efficacy. Some studies [6,7]
suggest a lack of evidence to support its use in the treat-
ment of chronic low back pain, while others found evi-
dence of benefit, or have concluded that there is a lack of
evidence of effect, rather than evidence of a lack of effect
[8,9]. The recent Cochrane Review (2005) [6] concluded
that there was limited or inconsistent evidence for TENS.
However, no other device has any better evidence of effi-
cacy and for this reason TENS was chosen as a comparator
treatment for a new device (FairMed) that has been devel-
oped to deliver sensory discrimination training in patients
with chronic back pain.
The aim of this study was to compare a novel sensory dis-
criminatory training device (FairMed) with TENS in a
Phase I clinical trial.
Methods
Trial design
The trial design was a single-blinded, longitudinal ran-
domised controlled, non-inferiority trial.
Ethical approval was given by the Milton Keynes Local
Research Ethics Committee (05/Q1603/34) and all
patients were approached and gave informed consent to
participate in the study.
Sample size
A power calculation for a non-inferiority trial was made
[10]. The non-inferiority limit (-d) was set at 20 on a 100
mm Visual Analogue Scale back pain scale as the primary
outcome measure. A minimal clinical difference change of
20 mm was set [11]. From a pilot sample of 50 current
patients the standard deviation (σ) of the VAS back was
2.07. δ = d/σ, δ = 0.966. This required 25 patients in each
arm of the trial, allowing for 10% attrition/non-compli-
ance rate, 55 subjects were required. This gave a 90%
power and a Type 1 error rate of 2.5%.
Participants
Patients referred to a Physiotherapy Department with a
diagnosis of chronic low back pain were recruited to the
study.
Inclusion criteria were patients aged over 18 years with a
diagnosis of chronic low back pain lasting a minimum of
3 months.
Exclusion criteria were patients with leg pain, those who
were current TENS users or patients where either of the
treatment modalities might harm them. This was based
on the warnings and precautions for the use of TENS
namely, patients with pacemakers, damaged or broken
skin, malignancy, poorly enervated areas and spinal infec-
tion.
Randomisation
Randomisation was performed using a random numbers
table. Randomisation was restricted to permuted blocks to
ensure equal numbers being allocated to each group. FourPage 2 of 8
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9 and two of 0–19. Each random permuted block was
transferred to a sequence of consecutively numbered,
sealed, opaque envelopes and these were stored in a
locked drawer until required. As each participant formally
entered the trial, the researcher opened the next envelope
in the sequence in the presence of the patient.
Blinding
We attempted to ensure integrity of blind assessment by
maintaining separation between the therapists providing
the treatment and those assessing We followed practical
tips to try and reduce 'unblinding' accepted within the
field [12], such as participants being reminded before
each assessment not to reveal details of their allocation
group.
Interventions
Patients were randomly allocated to use either TENS or
the FairMed device. For the TENS group a dual channel
portable TENS TPN 200 PLUS unit was used. Stimulation
was based upon best available evidence from the litera-
ture. For conventional TENS, parameters between 80–100
Hz and 100–200 μs are considered to be effective in the
treatment of chronic pain [6,9,13]. In studies specifically
on chronic low back pain populations [7,9], parameters
of 80 Hz/140 μs and 100 Hz/125 μs resulted in pain
reduction. It is suggested that patients use TENS as much
and as often as required [13]. Our protocol used stimula-
tion given in continuous trains at high frequency (80 Hz,
using square-wave 100 μs pulses). Two surface electrodes
(5 cm × 5 cm2 TPN 40 each) were placed in or adjacent to
the painful area at a distance of 5 cm–20 cm apart. The
intensity of TENS was adjusted to produce a tingling sen-
sation that was approximately 2–3 times the sensory
threshold.
The FairMed group received the device (Figure 1) which
includes 2 components: a hand held controller as subject
interface and an array of 16 vibrators closely applied to
the lumbar spine. One or more stimulator is activated ran-
domly and the subject responds by indicating which stim-
ulator(s) are active. The device display indicates if the
response is correct or not via a visual and auditory display.
The cycle is then repeated until the test session is com-
plete. This requires a high level of attention. Subjects were
asked to use the device for 30 minute sessions. The Fair-
Med is specifically not a device to deliver either painful
stimuli or massage. The stimulus is as localised as possi-
ble; it is brief and probably insufficient to impair position
sense. The device was designed to teach localised discrim-
ination of stimuli to the lumbar spine. The device was
conceived by JF, developed in conjunction with KB, and
prototype models were produced by a product design and
development consultancy, which completed pre-trial lab-
oratory testing.
Outcome measures
The outcome measures used in this trial were collected in
accordance with recommendations from the Initiative on
Methods, Measurement, and Pain Assessment in Clinical
Trials [IMMPACT]. These 6 core outcome domains are i)
pain, ii) physical functioning, iii) emotional functioning,
iv) participant ratings of improvement and satisfaction
with treatment, v) symptoms and adverse events, and vi)
participant disposition [14].
Pain was recorded using a 100 mm VAS recording
patient's present pain intensity level, their average and
worst pain intensity levels recorded over a week and aver-
aged [15].
Physical functioning was recorded using the Oswestry
Disability Index v 2.1 [16]. Functional physical tests – 5
minute walking distance, 1 minute stair climb and 1
minute standing up and sitting down from a chair were
used to assess those aspects of physical performance most
relevant to everyday activities [17].
Emotional functioning was assessed using a battery of
questionnaires, the Health Anxiety and Depression Scale
used to assess emotional functioning [18]; the Tampa
Scale for Kinesiophobia (TSK) to assess pain-related fear
of movement [19]; the Pain Coping Scale (PCS) to assess
the three components of catastrophising: rumination,
magnification and helplessness [20] and the Pain Self Effi-
cacy Questionnaire to assess people's self-efficacy beliefs
[21].
The FairMed; a) hand held controller and back array [b) pos-terior view and c) anterior view]Figu e 1
The FairMed; a) hand held controller and back array [b) pos-
terior view and c) anterior view].Page 3 of 8
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isfaction, the Patient Global Impression of Change scale
[22], was assessed, having been widely used in chronic
pain clinical trials e.g. Farrar, Young et al.[23], the PGIC
has been demonstrated to have validity and it provides a
responsive and readily interpretable measure. Participants
were asked how they felt after their treatment, firstly, with
regards to their ability to cope with their pain and, sec-
ondly, to their ability to perform everyday activities.
Participants completed outcome questionnaires at base-
line, 3 weeks, 6 weeks and 12 weeks. They underwent
functional testing at baseline and 3 weeks with a masked
assessor. Over the 3 weeks that participants used their
devices, they were asked to keep a daily pain diary.
Patients were explicitly asked about any adverse events
they experienced using the devices, and to record these in
their pain diary and by telephone report. An adverse event
is considered any unwanted effect detected in participants
of a clinical trial regardless of whether the effect can be
attributed to the intervention under evaluation [24].
Finally, information on participant disposition was col-
lected to document the recruitment of participants and
their progression through the trial, numbers receiving
intended treatment, those completing the study protocol
and analysed for the primary outcome [14,24].
Data analysis
Data were analysed using intention-to-treat analysis and
the statistical package SPSS 12.0.1 for Windows.
Non-parametric statistics were used to compare outcome
measures between groups (One way ANOVA). Statistical
significance was set at the p < 0.05 level.
Results
60 patients were randomised and recruited to the trial, 32
into the FairMed group and 28 into the TENS Group, 27
in each group completed the trial. Reasons for dropping
out varied: one participant was admitted to hospital for
spinal decompression surgery during his trial period, one
participant withdrew citing personal circumstances, and
four participants decided that they were unable to comply
with the protocol after they had begun on the trial. None
of the dropouts completed any re-assessments and so
could not be used in further analysis.
Other than the 6 participants who withdrew before com-
pletion of the trial, there was no further loss to follow up.
A CONSORT flow diagram is shown in figure 2.
CONSORT diagram showing flow of participants through each stage of the trialFigure 2
CONSORT diagram showing flow of participants through each stage of the trial.Page 4 of 8
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The mean age of participants was 53.4 years (SD 11.5).
Both TENS and FairMed groups comprised equal percent-
ages of men (50%) and women (50%). Analysis of all
baseline characteristics demonstrated no significant dif-
ference between groups (Table 1).
Primary measure – pain intensity
Table 2 summarises the changes in outcome measures
between baseline and 3 weeks. The primary outcome of
the study concerned the participants' change in baseline
pain intensity at 3 weeks. Worst, average and present pain
intensity were all recorded and summaries of the raw data
studied. The pattern of change in pain intensity scores was
similar for each sub-category and as such, only the change
in average VAS scores were analysed further. The mean dif-
ference in change of participants' average pain intensity
VAS scores between those participants in the TENS group
and those in FairMed group was -0.1., and was not statis-
tically significant (p = 0.82).
Secondary measures
Disability (Oswestry Disability Index)
The mean difference in change in ODI scores of those par-
ticipants in the FairMed and those in TENS groups was
0.4; this difference in change was not significant (p =
0.85).
Emotional functioning
No significant difference in change of scores of TSK, PSE,
PCS and HAD were detected for any of these outcome
measures.
Physical functioning
There were no significant differences in change of scores
for physical functioning using the 1 minute sit to stand, 1
minute stair and 5 minute walk test scores at baseline and
at 3 weeks.
Improvement and satisfaction ratings
In the FairMed group, 27% of participants stated that they
were more able to cope with pain at 3 weeks; in the TENS
group, this number was to 45%. However, 11% of TENS
group participants also stated that they were less able to
cope with pain at 3 weeks. 73% of FairMed group partici-
pants stated no change in their ability to cope with pain,
compared to 44% in the TENS group.
Discussion
The FairMed is a novel device and as such there are no
existing data on effectiveness. It is difficult to establish
what is a fair comparator to use in a trial with a new
device. Whilst the Cochrane review of TENS concluded
that there was limited evidence for TENS [6], there are no
other devices that provide any better evidence of efficacy,
nor any which have stood the test of time as well as TENS.
For this reason TENS was chosen as a comparator treat-
ment for a new device designed to help those patients
with chronic back pain who continue to have serious dif-
ficulties, despite not being a treatment endorsed by cur-
rent guidelines [1].
The findings of this trial demonstrate no significant differ-
ence in pain intensity reduction between the FairMed and
TENS. This is in keeping with other trials investigating
sensory changes, such as the findings of Guieu et al. [25]
and Lundeberg [26] who also found no significant differ-
ence in pain reduction between vibratory stimulation and
TENS in patients suffering with chronic musculoskeletal
pain. Both trials used a control of a similar high frequency
TENS and vibration protocol to the ones in the trial. There
is a plethora of different outcome measures that can be
Table 1: Participant Baseline Characteristics
Treatment Age 
(Years)
Average 
Pain 
Intensity 
(VAS 0–10)
Oswestry 
Disability 
Index 
(0–100%)
PSE 
(0–60)
TSK 
(17–60)
PCS 
(0–52)
Sit to 
Stand 
(N°/min)
Stair Climb 
(N°/min)
Walk Distance 
(metres/5 min)
FairMed N 32 (16 male; 
16 female)
32 32 32 32 32 32 32 32
Mean 52.7 6.3 40.8 31.0 40.4 19.6 13.7 6.5 235.6
Std. 
Deviation
10.7 1.9 15.9 11.2 7.6 12.0 7.6 2.7 103.2
Range 28 – 73 2 – 9 12 – 80 8 – 57 23 – 51 2 – 47 2 – 38 0 – 11.5 40 – 400
Median 55 6 40 30 42 20.5 13 6 260
IQR 47 – 59 5 – 8 30.5 – 47.5 21.8 – 37 34 – 46.8 10 – 26.5 8.5 – 16 5.3 – 8 160 – 300
TENS N 28 (14 male; 
14 female)
28 28 28 28 28 28 28 28
Mean 54.1 6.6 42.8 27.6 41.3 23.0 12.7 6.7 219.6
Std. 
Deviation
12.5 1.4 14.8 10.1 7.4 11.3 6.7 3.0 111.7
Range 27 – 74 4 – 10 18 – 74 8 – 44 29 – 55 5 – 44 4 – 29 1 – 12.5 0 – 400
Median 55 7 40.1 27 42 22 11 6.5 250
IQR 42.5 – 65.8 5 – 7 30.8 – 53.5 21.3 – 36 34 – 46.8 14.3 – 28.8 9 – 17 4.5 – 9 100 – 320Page 5 of 8
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physical outcome measures chosen were a walk test,
timed stair climb and sit to stand. These physical tests
have been advocated by other trial designs [17] and
reported for reliability in a similar clinical population to
the one in this study [27], hence the rationale for their use.
However, it is possible that selection of physical perform-
ance measures that stressed the spine more specifically,
such as loaded forward reach may have been more
responsive to change in this patient population.
The theory for the analgesic effect of TENS is suggested to
be as a result of counter stimulation of the nervous system
modifying the perception of pain [5]. There is evidence to
suggest that this same theory could be applied to the Fair-
Med. Studies have demonstrated that superficial and deep
mechanoreceptors exist with a high sensitivity to vibratory
stimulation [26,28,29]. With a surface area of almost 500
cm2, the FairMed stimulates a large region of the lumbar
spine and underlying tissues, indicating that pain allevia-
tion could be attributed to the activation of these recep-
tors.
Functional magnetic resonance imaging (fMRI) of sub-
jects has revealed reduced activity in the anterior cingu-
lated, insula and thalamus; some of the key pain
processing areas of the brain. There is evidence to suggest
that the same is true for cognitively demanding distrac-
tion. Bantick et al [30] reported decreased perception of
painful stimuli in subjects receiving noxious thermal stim-
ulus whilst engaged in a cognitively demanding task.
Using fMRI, decreased activation in the same key compo-
Table 2: Change in outcome measures between baseline and 3 weeks – group differences.
OUTCOME MEASURE MEAN SD LOWER C.I. (95%) UPPER C.I. (95%) SIGNIFICANCE*
VAS (Average)
FairMed -0.8 1.8 -1.5 -0.1 0.83
TENS -0.7 1.4 -1.3 -0.1
PSE
FairMed 1.9 7.8 -1.0 4.8 0.21
TENS 4.4 7.5 1.5 7.4
TSK
FairMed -1.8 5.8 -4.0 0.3 0.94
TENS -2.0 7.7 -5.0 1.1
PCS
FairMed -1.6 5.4 -3.6 0.4 0.84
TENS 2.0 7.7 -5.0 1.1
ODI
FairMed -0.6 8.7 -3.8 2.7 0.85
TENS -0.9 5.1 -3.0 1.1
HAD-A
FairMed -1.4 2.7 -2.4 -0.4 0.14
TENS -0.3 3.0 -1.4 0.9
HAD-D
FairMed -0.2 2.0 -1.0 0.5 0.49
TENS -0.6 1.9 -1.3 0.1
Sit to Stand
FairMed 1.0 2.1 0.1 1.8 0.90
TENS 1.0 2.2 0.1 1.9
Stairs
FairMed 0.4 1.9 -0.4 1.1 0.81
TENS 0.5 1.0 0.1 0.9
Walk Distance
FairMed 3.1 41.4 -12.6 18.9 0.58
TENS 9.1 39.2 -6.4 24.6
SD (Standard Deviation).
C.I. (Confidence Interval).
VAS (Visual Analogue Scale).
PSE (Pain Self-Efficacy).
TSK (Tampa Scale for Kinesiophobia).
PCS (Pain Catastrophising Scale).
ODI (Oswestry Disability Index).
HADS-A (Hospital Anxiety & Depression Scale – Anxiety).
HADS-D (Hospital Anxiety & Depression Scale – Depression).
(* p-value from One-Way ANOVA on mean change scores across treatments).Page 6 of 8
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Although these results are based on acute experimentally
induced pain, modulation of chronic pain could conceiv-
ably be achieved by the FairMed through interference
from vibratory stimulation and cognitive regulation of
attention. Furthermore, Flor et al [7] demonstrated a
reduction in phantom limb pain following a treatment
programme using sensory discrimination training, dem-
onstrated to be as a result of cortical reorganisation in the
primary somatosensory cortex.
The study was severely limited by the functionality and
reliability of the prototype FairMed device. Of the 32
devices used, 13 had developed faults by the end of the
trial. Of the 32 participants randomised to the FairMed
group, 20 reported some kind of fault with its functional-
ity. Feedback from users of the FairMed device will be
used to develop a more reliable device. It would have been
preferable for this information to have been gathered
before the main trial, but this was not possible due to time
restrictions.
We recognise that this is a very difficult group to help and
any treatment is likely to be of limited benefit. Commer-
cially and practically it is difficult to demonstrate benefit
in such chronic pain populations and very large studies
are needed to show superiority. At the early stages in the
development of a new and initially expensive device, a
non-inferiority study is thus the only financially and prac-
ticably viable option. The main difficulties in the design
and conduct of a non-inferiority trial are the demonstra-
tion of assay sensitivity, bias from lack of masking and dif-
ficulty in establishing the non-inferiority margin. As a
consequence, the results of a non-inferiority trial are not
as credible as those from a successful superiority trial
[32,33]. However, a superiority trial requires a large posi-
tive mean difference and a small standard error of the
mean difference to demonstrate a significant difference
between interventions [33] and thus requires a much
larger sample size [32,34]. Alternatively, in order to estab-
lish assay sensitivity using a non-inferiority trial design, it
could be useful to include a placebo group in addition to
the active control group [32]. However, given the rela-
tively small difference hypothesised to exist between the
FairMed and TENS, the sample sizes required to success-
fully demonstrate superiority or to include a third inter-
vention group were considered prohibitive. Nevertheless,
with greater resources, a more robust trial design could
have been adopted.
Conclusion
The findings presented in this study are not able to dem-
onstrate a reduction in chronic low back pain using the
FairMed. None-the-less, cortical reorganisation through
sensory discrimination may be a mechanism through
which the FairMed could modulate CLBP. Further work to
explore these mechanisms is still needed to expand our
understanding of chronic pain and the role of neuro-mod-
ulation in the transition from acute to chronic LBP.
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